Pharma Sector Check: Growth Is Back With A Lag; Marketing Overhead Reaches At Pre-Covid-19 Levels, Says Prabhudas Lilladher
An employee holds Ramipril capsules for a photograph inside a coating unit at the Lupin Ltd. pharmaceutical plant in Salcette, Goa, India. (Photographer: Dhiraj Singh/Bloomberg)

Pharma Sector Check: Growth Is Back With A Lag; Marketing Overhead Reaches At Pre-Covid-19 Levels, Says Prabhudas Lilladher

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Prabhudas Lilladher Report

Indian pharma market growth recovered in December 2020 to 8.5% after weak November 2020, due to festive season and fears related to lockdown.

The key reasons for growth in December 2020 (as from November 2020 onwards) are -

  1. Medial representatives back on field with full force and
  2. marketing activities reaching pre-Covid-19 levels.

Digital marketing continues to be an integral part of marketing activities, which actually started as a cost saving activity during lockdown.

Click on the attachment to read the full report:

Prabhudas Lilladher Pharma Sector Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.